Company: WHWK
Filing Date: 2025-04-25
Form Type: 424B5
Source: 0001193125-25-097064
Chunk: 16

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-04-25
Form: 424B5
Chunk 16
---
 stock.

Our common stock is listed on the Nasdaq Capital Market and trades under the symbol “WHWK.” The transfer agent of our common stock is Equiniti
Trust Company, LLC.

TD Cowen and/or its affiliates have provided, and may in the future provide, various investment banking and other financial
services for us and our affiliates, for which services they have received, and may in the future receive, customary fees.

S-14

LEGAL MATTERS

The validity of the issuance of the securities offered hereby will be passed upon by our counsel, Wilson Sonsini Goodrich & Rosati P.C., San
Diego, California. TD Securities (USA) LLC is being represented in connection with this offering by Cooley LLP, New York, New York. Certain members of, and investment partnerships comprised of members of, and person associated with, Wilson Sonsini
Goodrich
& Rosati, Professional Corporation, directly or indirectly own less than 0.1% of the outstanding shares of our common stock.

EXPERTS

The consolidated financial statements of Whitehawk Therapeutics, Inc. as of December 31, 2024 and 2023, and for the years then
ended incorporated by reference in this prospectus and in the registration statement have been so incorporated in reliance on the report of BDO USA, P.C., an independent registered public accounting firm, given on the authority of said firm as
experts in auditing and accounting.

WHERE YOU CAN FIND MORE INFORMATION

We have filed with the SEC a registration statement on Form S-3 under the Securities Act, of which this
prospectus supplement and the accompanying prospectus form a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus certain information included in the registration statement. For
further information about us and the securities we are offering under this prospectus supplement and the accompanying prospectus, you should refer to the registration statement and the exhibits and schedules filed with the registration statement.
With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text
of the agreement or document, a copy of which has been filed as an exhibit to the registration statement.

We file reports, proxy statements and
other information with the SEC under the Exchange Act. The SEC maintains an Internet website that contains reports, proxy statements and other information about issuers, like